HK Stock MarketDetailed Quotes

02877 SHINEWAY PHARM

Watchlist
  • 9.730
  • -0.200-2.01%
Market Closed Mar 28 16:08 CST
8.05BMarket Cap7.52P/E (TTM)

About SHINEWAY PHARM Company

China Shenwei Pharmaceutical Group Co., Ltd. is a large-scale enterprise group specializing in R&D, production and sales of modern traditional Chinese medicines. It is a national top 100 pharmaceutical company, a national top 50 proprietary Chinese medicine company, and a company listed on the main board of the Hong Kong Stock Exchange. In 2004, the comprehensive strength of Shenwei Pharmaceutical rose to the top ten Chinese medicine enterprises in the country. Shenwei Pharmaceutical products use the “Shenwei” and “Five Fortune” trademarks. “Shenwei” is a well-known Chinese trademark recognized by the State Administration for Industry and Commerce, and “Five Fortune” is a famous trademark of Hebei Province, all of which have established a high-quality and reliable image among customers. In 2003, Shenwei Pharmaceutical fully passed the national GMP certification. In June 2004, Shenwei Pharmaceutical obtained the IMS certificate issued by the British Standards Institute (BSI), making it the first Chinese medicine enterprise group in the country to pass the international certification of the three systems of quality control system (ISO9001) /environmental management system (ISO14001) /occupational safety and health management system (OHSAS18001) and their integrated system. In July 2004, Shenwei Pharmaceutical Marketing Company passed the national GSP certification. Shenwei Pharmaceutical mainly targets the three rapidly growing target markets for middle-aged and elderly medicine, children's medicine, and antiviral medicine. It focuses on developing new dosage forms and products of modern traditional Chinese medicine, and has formed a strong advantageous product portfolio mainly based on prescription drugs and characterized by the three major dosage forms of modern traditional Chinese medicine injections, softgels, and granules. Shenwei Pharmaceutical is currently the largest domestic manufacturer of Qingkailing injections, Shenmai injections, and Xinbraqing softgels. Eleven varieties, including Shenwei Brand Agastache Zhengqi Softgels and Qingkailing Softgels, are listed as national protected varieties of traditional Chinese medicine; Wufu Xinnaoqing Softgels and Shenwei Brand Agastache Zhengqi softgels are recognized as green standard products by the China Chamber of Commerce for Import and Export of Medicines and Health Products. Shenwei Pharmaceutical has modern production facilities, strict on-site management, and large-scale commercial production capabilities. It can produce high-tech dosage forms, such as modern traditional Chinese medicine injections and modern traditional Chinese medicine softgels, and effectively control costs and improve quality. The traditional Chinese medicine extraction and injection workshop was listed by the National Development and Reform Commission as a “demonstration project for the integration of advanced process units for traditional Chinese medicine preparations and high-tech industrialization of automated production process control”. Shenwei Pharmaceutical pays attention to the quality of Chinese herbal medicines from the source, and has successively established green Chinese herbal medicine planting bases in places such as Jilin, Shandong, Hebei, and Xinjiang. At the same time, through the introduction of advanced production equipment and processes at home and abroad to strengthen enterprise management and improve product quality. Through comprehensive application of new technology, new processes and equipment for modern traditional Chinese medicine production, and the use of new technologies such as fingerprint maps, supercritical CO2 extraction, ultrafine grinding, controlled release administration, etc., it has fully introduced leading process equipment such as dynamic countercurrent extraction of traditional Chinese medicine, injection washing, drying and sealing production lines, and fully automatic packaging lines for soft capsules. It has widely applied computer control technology to standardize traditional Chinese medicine production, modernize traditional Chinese medicine dosage forms, and standardize production equipment for quality control Automate to make God powerful Modern traditional Chinese medicine products have met the modern standard of “safe, effective, stable, and controllable”, and have the advantages of “three small doses (low dose, low toxicity, low side effects), three effects (high efficiency, quick effect, long-term effect), and five convenient (production, transportation, administration, carrying, storage)”, so that traditional Chinese medicine synchronizes with modern life, so that good medicine is no longer bitter. Strong R&D capabilities are the foundation for the continuous development of Shenwei Pharmaceutical. Shenwei Pharmaceutical's New Drug Research and Development Center has senior professional and technical personnel, including postdocs, and is a young and energetic research team. Based on the concept of “market-oriented, technology-led, and modernized traditional Chinese medicine as the core”, the R&D center actively carries out pharmaceutical research and clinical research on new traditional Chinese medicines in fields such as medicine for middle-aged and elderly people, children's medicine, and antiviral medication. The company adopts a flexible approach of independent research and development and close cooperation with well-known scientific research institutions, and has the characteristics of low cost and high efficiency. In recent years, Shenwei Pharmaceutical has successfully completed large-scale commercial production of dozens of modern traditional Chinese medicine products such as Shenmai injection, Qingkailing injection, and Wufu Xinnao soft capsules. It has successively developed 8 new national medicines, 6 modern traditional Chinese medicines based on traditional recipes, and 12 projects under development, forming a new product pattern of “production generation, reserve generation, development generation”. Research on the National Class II New Drug - Fat Reduction Tongluo Softgel was included in the National High-Tech Research and Development Plan (863), a major science and technology project “Innovative Drugs and Modernization of Traditional Chinese Medicine”, and included by the National Development and Reform Commission in the 2004 “High-tech Industrialization Demonstration Project for Fat Reduction Tongluo Softgel” project. Shenwei Pharmaceutical has an extensive distribution network. The company's first-level distributors cover 30 provinces, autonomous regions and municipalities across the country, and promote Shenwei products to all target customers with the full cooperation of the Shenwei sales team and terminal promotion. The company has 15 varieties with annual sales exceeding 10 million yuan. Of these, the three varieties of Wufu Xinnao Qingqing softgels, Shenmai injections, and Qingkailing injections have annual sales of over 100 million yuan. In recent years, Shenwei Pharmaceutical has successively won hundreds of honorable titles, including the National “May Day” Labor Award and the National Advanced Group of Traditional Chinese Medicine. Li Zhenjiang, the chairman and president of the company, has successively won many honorary titles such as the National Pharmaceutical Industry Outstanding Entrepreneur and the National “May 1st” Labor Medal, and has received special allowances from the State Council government; in 2003, Li Zhenjiang was elected as a deputy to the 10th National People's Congress. In the next five years, Shenwei Pharmaceutical will continue to focus on R&D, production and sales of modern traditional Chinese medicine, increase the promotion of the Shenwei brand, and focus on cultivating core competitiveness in four areas: demand-oriented R&D, lean production requiring cost and quality, marketing based on traditional pipelines, terminal control as the ultimate goal, and Shenwei culture centered on refinement and realism, to build a first-class modern traditional Chinese medicine brand, and strive to become the best modern traditional Chinese medicine enterprise in China, leading modern traditional Chinese medicine and promoting the health industry.

Company Profile

Symbol02877
Company NameSHINEWAY PHARM
ISINKYG2110P1000
Listing Date12/02/2004
Issue Price4.36
Shares Offered200.00M share
Founded08/14/2002
RegistrationCayman Islands
ChairmanZhenjiang Li
SecretaryPinzheng Li
Audit InstitutionDeloitte & Touche Tohmatsu Certified Public Accountants
Company CategoryOverseas registration of Mainland Individuals control
Registered OfficeCricket Square, Hutchins Drive, P.O. Box 2681, Grand Cayman KY1-1111, Cayman Islands
Head Office and Principal Place of BusinessRoom 3109, 31st floor, Central Plaza, 18 Harbour Road, Wanchai, Hong Kong
Fiscal Year Ends12-31
Employees3533
MarketHong Kong motherboard
Phone(852)35210816;(852)98666868
Fax(852) 3521 0821
Emailmetluk@shineway.com.hk
Business China Shenwei Pharmaceutical Group Co., Ltd. is an investment holding company mainly engaged in R&D, manufacturing and marketing of modern traditional Chinese medicines. Its main products include injections, softgels and granules. The company's subsidiaries include Yuanda International Co., Ltd., Hongzhan International Co., Ltd., and Shenwei Pharmaceutical Marketing Co., Ltd.

Company Executives

  • Name
  • Position
  • Salary
  • Zhenjiang Li
  • Nomination Committee Chairman,Chairman,Executive Director
  • 4.46M
  • Yunxia Xin
  • Executive Director,Remuneration Committee Member
  • 3.11M
  • Huimin Li
  • Executive Director,Authorized Representative
  • 2.09M
  • Shunhui Liao
  • Nomination Committee Member,Audit Committee Chairman,Independent Non-Executive Director,Remuneration Committee Member
  • 138.00K
  • Yian Yao
  • Audit Committee Member,Independent Non-Executive Director,Nomination Committee Member
  • 35.00K
  • Guihua Wang
  • Remuneration Committee Chairman,Audit Committee Member,Independent Non-Executive Director
  • --
  • Wencheng Zhou
  • Non-Executive Director
  • 138.00K
  • Yudong Zhang
  • General marketing manager
  • --
  • Jingquan Kong
  • Director of Investor Relations
  • --
  • Pinzheng Li
  • Company Secretary,Finance Director,Authorized Representative
  • --
  • Tiejun Liu
  • VP
  • 91.00K

Analysis

Analyst Rating

No Data

Price Target

No Data

Heat List
HK
Overall
Symbol
Latest Price
%Chg